CDO1 and breast carcinoma: reported that siramesine and lapatinib can increase ROS production to induce ferroptosis in cells, while overexpression of CDO1 in breast cancer cells leads to a decrease in GSH levels, causing further accumulation of ROS, exacerbating ferroptosis in breast cancer cells (151).